PMID- 36996780 OWN - NLM STAT- MEDLINE DCOM- 20230706 LR - 20230914 IS - 1423-0097 (Electronic) IS - 1018-2438 (Linking) VI - 184 IP - 7 DP - 2023 TI - Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria. PG - 643-655 LID - 10.1159/000529250 [doi] AB - INTRODUCTION: Chronic urticaria (CU) is a common skin condition that can be divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Omalizumab is one treatment option for CU, but currently there are limited clinical studies of omalizumab's efficacy for treating CU in Chinese patients. This study sought to investigate the efficacy and safety of omalizumab treatment for CU patients in a Chinese patient population. Specifically, we aimed to compare the differential efficacy of omalizumab for CSU and CIndU patients and predict risk factors for recurrence. METHODS: We completed a retrospective clinical data review of 130 CU patients who received omalizumab treatment from August 2020 to May 2022, with a maximum follow-up period of 18 months. RESULTS: A total of 108 CSU patients and 22 CIndU patients were included in the study. After treatment with omalizumab, the response rate in the CSU group was higher than that in the CIndU group (93.5% vs. 68.2%), and CSU patients accounted for a higher proportion of responders and early responders (responders: 87.1% vs. 12.9%, p < 0.001; early responders: 95.7% vs. 4.3%, p = 0.001). Nonresponders had lower total immunoglobulin E (IgE) levels (75.0 vs. 167.5 IU/mL, p = 0.046) and a relatively shorter duration of treatment (1.0 vs. 3.0 months, p = 0.009) compared to responders. Early responders had shorter disease duration (1.0 vs. 3.0 years, p = 0.028), higher baseline UCT (4.0 vs. 2.0, p = 0.034), lower baseline DLQI (18.0 vs. 18.5, p = 0.026), and shorter total treatment time (2.0 vs. 4.0 months, p < 0.001) compared to late responders. All adverse events reported during treatment were mild. Seventy-four patients with CU discontinued the drug after achieving complete disease control, of which 26 (35.1%) relapsed for 2.0 months (interquartile range: 1.0-3.0 months). Compared with nonrelapsed patients, relapsed patients often had other allergic diseases (42.3% vs. 18.8%, p = 0.029), higher basal levels of total IgE (263.0 vs. 140.0 IU/mL, p = 0.033), and longer disease duration (4.2 vs. 1.0 years, p = 0.002). Relapsed patients could still achieve good disease control after restarting omalizumab therapy. CONCLUSION: Omalizumab was effective and safe for CSU and CIndU patients. Patients with CSU responded more quickly to omalizumab and showed a relatively better treatment effect. However, there was a possibility of relapse after discontinuation of omalizumab after complete control of CU, and in these cases, restarting omalizumab treatment after relapse was effective. CI - (c) 2023 S. Karger AG, Basel. CN - Yang FAU - Yu, Rentao AU - Yu R AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Qian, Weilu AU - Qian W AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zheng, Qiu AU - Zheng Q AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xiong, Jianxia AU - Xiong J AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Shuang AU - Chen S AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Aijun AU - Chen A AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Jin AU - Chen J AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Fang, Sheng AU - Fang S AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Huang, Kun AU - Huang K AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Cai, Tao AU - Cai T AD - Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20230330 PL - Switzerland TA - Int Arch Allergy Immunol JT - International archives of allergy and immunology JID - 9211652 RN - 2P471X1Z11 (Omalizumab) RN - 0 (Anti-Allergic Agents) RN - 37341-29-0 (Immunoglobulin E) SB - IM MH - Humans MH - Omalizumab/therapeutic use/adverse effects MH - *Anti-Allergic Agents MH - Chronic Inducible Urticaria MH - Retrospective Studies MH - *Urticaria/drug therapy MH - *Chronic Urticaria/drug therapy MH - Chronic Disease MH - Recurrence MH - Immunoglobulin E MH - Treatment Outcome OTO - NOTNLM OT - Chronic urticaria OT - Omalizumab OT - Relapse OT - Treatment results EDAT- 2023/03/31 06:00 MHDA- 2023/07/06 06:42 CRDT- 2023/03/30 18:23 PHST- 2022/11/07 00:00 [received] PHST- 2023/01/13 00:00 [accepted] PHST- 2023/07/06 06:42 [medline] PHST- 2023/03/31 06:00 [pubmed] PHST- 2023/03/30 18:23 [entrez] AID - 000529250 [pii] AID - 10.1159/000529250 [doi] PST - ppublish SO - Int Arch Allergy Immunol. 2023;184(7):643-655. doi: 10.1159/000529250. Epub 2023 Mar 30.